A total of 3.1 million courses of molnupiravir, an investigational oral antiviral for COVID-19, have been provided to the US government for allocation across the country, according to a press release issued by Merck and Ridgeback Biotherapeutics.
Molnupiravir is an orally administered form of a ribonucleoside analogue that inhibits the replication of SARS-CoV-2. The drug is authorized for emergency use by the Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults 18 years of age and older with positive results of direct SARS-CoV-2 viral testing and who are at risk for progressing to severe COVID-19 and/or hospitalization, and for whom alternative COVID-19 treatment options authorized by FDA are not accessible or clinically appropriate.
“In line with our commitment to accelerating access to molnupiravir in the US, we have now supplied more than 3 million courses to the US government within approximately 7 weeks of receiving Emergency Use Authorization (EUA) from the US Food and Drug Administration,” said Robert M. Davis, chief executive officer and president, Merck.
The authorized dose for molnupiravir is 800mg (four 200mg capsules) taken orally every 12 hours for 5 days. The treatment should be initiated as soon as a diagnosis of COVID-19 has been made and within 5 days of symptom onset.
To help providers identify locations that have received shipments of molnupiravir, in addition to other COVID-19 therapeutics under the FDA’s EUA (eg, Paxlovid, Evusheld), the US Department of Health and Human Services (HHS) has created a public website.
Merck and Ridgeback announce that 3.1 million courses of molnupiravir, an investigational oral antiviral COVID-19 medicine, have been supplied to the US government for use in the United States. News release. February 8, 2022. https://www.businesswire.com/news/home/20220208005551/en/Merck-and-Ridgeback-Announce-That-3.1-Million-Courses-of-Molnupiravir-an-Investigational-Oral-Antiviral-COVID-19-Medicine-Have-Been-Supplied-to-the-U.S.-Government-for-Use-in-the-United-States
This article originally appeared on MPR